Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction

Beshay N. Zordoky, Miranda M. Sung, Justin Ezekowitz, Rupasi Mandal, Beomsoo Han, Trent C. Bjorndahl, Souhaila Bouatra, Todd Anderson, Gavin Y. Oudit, David S. Wishart, Jason R. B. Dyck, Alberta HEART

Abstract

Background
Heart failure (HF) with preserved ejection fraction (HFrEF) is increasingly recognized as an important clinical entity. Preclinical studies have shown differences in the pathophysiology between HFrEF and HF with reduced ejection fraction (HFrEF). Therefore, we hypothesized that a systematic metabolomic analysis would reveal a novel metabolomic fingerprint of HFrEF that will help understand its pathophysiology and assist in establishing new biomarkers for its diagnosis.

Methods and Results
Ambulatory patients with clinical diagnosis of HFrEF (n = 24), HFrEF (n = 20), and age-matched non-HF controls (n = 38) were selected for metabolomic analysis as part of the Alberta HEART (Heart Failure Etiology and Analysis Research Team) project. 181 serum metabolites were quantified by LC-MS/MS and 1H-NMR spectroscopy. Compared to non-HF control, HFrEF patients demonstrated higher serum concentrations of acylcarnitines, carnitine, creatinine, betaine, and amino acids; and lower levels of phosphatidylcholines, lysophosphatidylcholines, and sphingomyelins. Medium and long-chain acylcarnitines and ketone bodies were higher in HFrEF than HFrEF patients. Using logistic regression, two panels of metabolites were identified that can separate HFrEF patients from both non-HF controls and HFrEF patients with area under the receiver operating characteristic (ROC) curves of 0.942 and 0.981, respectively.

Conclusions
The metabolomics approach employed in this study identified a unique metabolomic fingerprint of HFrEF that is distinct from that of HFrEF. This metabolomic fingerprint has been
utilized to identify two novel panels of metabolites that can separate HFpEF patients from both non-HF controls and HFrEF patients.

Clinical Trial Registration
ClinicalTrials.gov NCT02052804

Introduction
Heart failure (HF) affects more than 5 million people in North America, with approximately 825,000 incident cases per year in the United States alone [1]. Although the incidence of HF has declined since the mid-1990s, the prevalence of HF is still increasing due to improved survival after HF diagnosis [2]. Despite the advent of several new medications, devices and multidisciplinary clinics to manage HF, the prognosis of HF remains poor, with an estimated survival rate of 50% within 5 years after initial HF diagnosis [1]. During the initial clinical work-up for patients with confirmed or suspected HF, patients are classified via ejection fraction (EF) into one of two groups: a) HF with reduced ejection fraction (HFrEF) or b) HF with preserved ejection fraction (HFpEF). HFpEF is becoming increasingly recognized as a distinct clinical entity and accounts for 30–40% of all HF cases [3, 4]. HFpEF is broadly defined as a clinical syndrome in which patients present with symptoms and signs of HF, but normal or near normal left ventricular (LV) systolic function, with or without evidence of abnormal diastolic function (e.g. abnormal LV relaxation, filling, diastolic distensibility and diastolic stiffness) [5]. Patients with HFpEF have a similar one-year mortality as patients with HFrEF [6]. Although many therapies exist for HFrEF, no therapy to date has shown any significant reduction in morbidity and mortality for HFpEF [7].

Several pathophysiologic differences between HFpEF and HFrEF have been identified [8]; however, the molecular pathways responsible for these differences are still poorly understood. Metabolomic analysis has been frequently utilized to elucidate new molecular and pathophysiologic processes of several cardiovascular diseases and heart failure [9–12]. Accordingly, a unique metabolomic fingerprint of HFpEF patients may enhance our understanding of the molecular/physiological basis of HFpEF, which may lead to the development of new therapies to specifically treat HFpEF.

Current definitions for the diagnosis of HFpEF, including those endorsed by clinical guidelines [7, 13], are neither sensitive nor specific, and lack the diagnostic accuracy needed for clinical use [14]. Although several biomarkers have been utilized to help in HF diagnosis (e.g. B-type Natriuretic Peptide (BNP) and N-terminal pro-BNP (NT-proBNP)), most of these biomarkers do not provide enough utility to distinguish between HFrEF and HFpEF in clinical practice [15]. Since metabolomics is increasingly being utilized to identify new biomarkers in cardiovascular medicine [16], the second objective of this study is to identify novel metabolite biomarkers to distinguish patients with HFpEF from control subjects, and to distinguish between the two clinical syndromes of HFpEF and HFrEF.

Materials and Methods
Participants
Ambulatory patients were selected for metabolomic analysis as part of the Alberta HEART (Heart Failure Etiology and Analysis Research Team; www.albertaheartresearch.ca) project.
Totally 82 subjects were included in this metabolomics sub-study. Among these 82 subjects, there were 24 patients with HFpEF, 20 patients with HFrEF, and 38 control subjects without heart failure.

Only 82 subjects were included in this metabolomics sub-study. Among these 82 subjects, there were 24 patients with HFpEF, 20 patients with HFrEF, and 38 control subjects without HF. Participants in this metabolomics sub-study were recruited from January 2010 till March 2013 (Fig 1). In the current study, control subjects are defined as individuals with normal LV function as assessed by echocardiography and without symptoms suggestive of a clinical diagnosis of HF. The control subjects included age- and gender-matched individuals with no evidence of coronary artery disease (CAD), hypertension, diabetes mellitus, organ disease or replacement therapies; no evidence of inflammatory or autoimmune conditions and not on cardiac medications. Additional controls included age- and gender-matched patients with high risk of developing HF but no clinically overt HF; these latter patients are generally asymptomatic (no dyspnea or fatigue) and have no known prior HF or other overt cardiovascular disease. The exclusion criteria included: severe liver disease, end stage renal disease (with GFR < 15 ml/min), active or ongoing malignancy, or cardiac surgery, major surgery, or major...
cardiovascular event in the past 3 months. All enrolled patients undergo blinded adjudication by cardiologists experienced in adjudication. For the purposes of this study, patients with HF were further adjudicated as HfP EF (n = 24) or HfR EF (n = 20) using a left ventricular ejection fraction (LVEF) of 45% as a cutoff value [5, 13]. Detailed clinical, biomarker and imaging data were collected at the time of enrolment and echocardiograms were performed in 2D, 3D, and contrast modalities and interpreted by cardiologists blinded to the metabolomic analysis. The research protocol used in this study received ethics board approval at the Universities of Alberta and Calgary. Written informed consent was obtained from all subjects.

Measurement of cardiac peptides
Plasma BNP levels were assessed as previously described [18] using a Biosite Triage reagent pack (Biosite Inc., San Diego, CA, USA), while plasma NT-proBNP analysis was performed with the commercially available immunoassay using the Elecsys 2010 proBNP assay (Roche Diagnostics GmbH, Manheim, Germany) read in an automated Access immunoanalyzer (Beckman-Coulter, Fullerton, CA, USA) at Alberta Health Services Laboratory Services—Edmonton, Alberta.

Combined direct flow injection and LC-MS/MS compound identification and quantification
We applied a targeted quantitative metabolomic approach to analyze the serum samples using a commercially available metabolomics system (Absolute IDQ p180 Kit—BIOCRATES Life Sciences AG, Austria). This kit, in combination with an ABI 4000 Q-Trap (Applied Biosystems/ MDS Sciex) mass spectrometer equipped with a reverse-phase HPLC column, can be used for the targeted identification and quantification of up to 180 different endogenous metabolites including amino acids, acylcarnitines, biogenic amines, glycerophospholipids, sphingolipids and sugars. The kit contains reagents for the derivatization and extraction of analytes (for maximal separation), along with the software to support selective mass-spectrometric detection via multiple reaction monitoring (MRM) pairs (for metabolite identification and quantification). Isotope-labeled internal standards and other internal standards are integrated in the kit plate filter to permit absolute metabolite quantification. All the serum samples were analyzed with the AbsoluteIDQ p180 kit using the protocol described in the AbsoluteIDQ user manual.

Sample preparation and NMR spectroscopy
Serum samples were prepared as described previously [19]. A total of 350 μL of sample was transferred to a micro-cell NMR tube (Shigemi, Inc., Allison Park, PA) for subsequent spectral analysis. All 1H-NMR spectra were collected on a 500 MHz Inova NMR spectrometer (Varian Inc. Palo Alto, CA) equipped with a 5 mm HCN Z-gradient pulsed-field gradient (PFG) room-temperature probe as described previously [19].

Statistical analysis
For demographic and clinical data, continuous data are presented as median ± interquartile range (IQR), while categorical data are presented as raw values and percentages from the total. Continuous variables were compared using a Kruskal-Wallis test, while categorical data were compared through a Chi-square test. In situations where less than 5 observations were available, a Fisher’s Exact test was applied. A p-value < 0.05 was considered significant for all statistical analyses.

For metabolomic data analysis, log-transformation was applied to all quantified metabolites to normalize the concentration distributions. Heat maps were generated with the concentrations
of potential candidate metabolites, which were extracted with univariate analysis. It was generated without hierarchical cluster analysis unlike usual structure of heat map. It was simply arranged by grouping similar metabolites together for use in pathway analysis through intuitive pattern discovery. The heat map displays an increase in each metabolite in relative concentration as a red color and a decrease in a metabolite as a blue color. The metabolites are listed at the left side of each row, and the subjects are shown at the bottom of each column. Logistic regression (LR) was performed to find the most parsimonious model to discriminate each case group from the other control groups using the minimum number of metabolites. In order to optimize the metabolite (i.e. variable) selection, a technique called least absolute shrinkage and selection operator (LASSO) was also performed. A receiver operating characteristic (ROC) curve was determined for each LR model. The ROC calculations included bootstrap 95% confidence intervals for the desired model specificity as well as other measures including accuracy and false discovery rates (FDR). In addition, permutation tests (n = 2,000) were performed to validate the statistical significance of each LR model [20]. The p-value of the permutation test was calculated as the proportion of the times that the class separation for a randomly labelled sample was at least as good as the one based on the original data (one-sided p value) [21].

LR models to discriminate HFpEF from HFrEF, or HF from controls were constructed. To assess if a biomarker or a panel of metabolites improved the categorization of a patient, the ROC area-under-the-curve (AUC), net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated using the methods described by Pencina et al. [22]. All of the statistical analyses were carried out using the R statistical software (http://www.r-project.org).

Results

Demographics and group differences

Table 1 shows the baseline characteristics of the study groups. There was no significant difference in the prevalence of hypertension or diabetes between the three groups. HFpEF patients had significantly higher male to female ratio, older age, higher prevalence of dyslipidemia and atrial fibrillation than the non-HF control group. However, there was no significant difference in these characteristics between HFrEF patients and non-HF controls. Patients with HF (both HFpEF and HFrEF) had a higher body mass index, higher prevalence of CAD, and were on more cardiovascular medications than non-HF controls. There was no significant difference between the HFpEF and HFrEF groups with regard to baseline characteristics, NYHA classification, cardiovascular diseases, or the use of cardiovascular medications, with the exception that CAD was more prevalent in patients with HFrEF (Table 1). BNP and NT-proBNP levels were higher and LVEF was lower in both HF groups than in the control subjects. Similarly, the BNP and NT-proBNP levels were higher and the LVEF was lower in the HFrEF group than in the HFpEF group (Fig 2).

Metabolomic differences between HFpEF and controls

Serum metabolomic analysis of a total of 181 analyzed metabolites from DI-MS (148 metabolites) and NMR (33 metabolites) revealed that the serum concentrations of short-chain, medium-chain, and long-chain acylcarnitines, carnitine, creatinine, betaine, and several amino acids were higher in HFpEF patients than non-HF controls (Fig 3, S1 Table). In addition, the serum concentrations of phosphatidylcholines (PC), lysophosphatidylcholines (LysoPC), and sphingomyelins (SM) were lower in HFpEF patients than non-HF controls (Fig 3, S1 Table).

To identify potential metabolite biomarkers, LR was performed to find the most parsimonious model to discriminate HFpEF patients from the non-HF controls. Since there was a
significant difference in age and gender between patients with HFpEF and non-HF controls, the LR analysis was performed only for the subset of metabolites which had no significant correlation with these demographic variables. A small number of metabolites including octanoyl-carnitine, arginine, asparagine, LysoPC(C18:2), and SM(C20:2) was able to discriminate HFpEF patients from the non-HF controls. Receiver operating characteristic (ROC) curve analysis using only these selected metabolites produced an area under the curve (AUC) of 0.924 (Fig 4A and Table 2). The permutation test’s result (p-value < 0.0005) for model validation indicated that the model was highly significant.

A separate LR model was developed incorporating a panel of three metabolites (octanoyl-carnitine, arginine, and SM(C20:2) (Fig 4B–4D)) along with NT-proBNP to produce a ROC curve with an AUC of 0.942 (Fig 4A and Table 2). The permutation test’s result (p-value < 0.0005) for this model indicated that it, too, was highly significant. The biomarker models that included metabolites had higher AUCs, and higher sensitivity/specificity than models that did not include metabolites. Overall, the best model was the one that combined NT-proBNP and metabolite data (Fig 4A, Table 2, and S4 Table). However, the difference between the metabolite-only model and the metabolites+NT-proBNP model was not statistically

| Table 1. Demographic Details of Participants. |
|-----------------------------------------------|
| Control | HFP EF | HFR EF |
| N | 38 | 24 | 20 |
| **Baseline Characteristics** | | | |
| Male, N (%) | 18 (47.37) | 18 (75) * | 14 (70) |
| Age | 61.50(53.75–69.00) | 67.50 *(57.50–74.75) | 63.50(56.00–69.00) |
| **NYHA Classification** | | | |
| Class I, N(%) | NA | 3 (12.5) | 1 (5) |
| Class II, N(%) | NA | 15 (62.5) | 11 (55) |
| Class III, N(%) | NA | 6 (25) | 7 (35) |
| Class IV, N(%) | NA | 0 (0) | 1 (5) |
| **Other cardiovascular Diseases or Risk Factors** | | | |
| CAD, N(%) | 5 (13.2) | 10 (41.7) * | 15 (75) * † |
| Dyslipidemia, N(%) | 13 (43.2) | 17 (70.8) * | 13 (65) |
| Hypertension, N(%) | 22 (57.9) | 15 (62.5) | 10 (50) |
| Diabetes, N(%) | 9 (23.7) | 10 (41.6) | 5 (25) |
| Atrial Fibrillation, N(%) | 7 (18.4) | 11 (45.8) * | 5 (25) |
| BMI (kg/m²) | 27.74(24.03–30.80) | 31.07 * (29.13–36.13) | 30.31 * (26.50–33.96) |
| **Cardiovascular Medications** | | | |
| Beta blockers, N(%) | 8 (21.1) | 21 (87.5) * | 20 (100) * |
| ACEI or ARB, N(%) | 16 (42.1) | 20 (83.3) * | 18 (90) * |
| Spironolactone, N(%) | 1 (2.6) | 6 (25) * | 7 (35) * |
| Diuretic, N(%) | 4 (10.5) | 18 (75) * | 13 (65) * |
| Statins, N(%) | 15 (39.5) | 19 (79.2) * | 12 (60) |
| CCB, N(%) | 9 (23.7) | 8 (33.3) | 4 (20) |
| Aspirin, N(%) | 5 (13.2) | 16 (66.7) * | 15 (75) * |

* p-value < 0.05 compared to control
† p-value < 0.05 compared to HFP EF

HFpEF = Heart Failure with Preserved Ejection Fraction, HFR EF = Heart Failure with reduced Ejection Fraction, NYHA = New York Heart Association, CAD = Coronary Artery Disease, LVEF = Left Ventricular Ejection Fraction, BMI = Body Mass Index, BNP = B-type Natriuretic Peptide, NT-proBNP = N terminal pro-BNP, ACEI = Angiotensin Converting Enzyme Inhibitor, ARB = Angiotensin Receptor Blocker, CCB = Calcium Channel Blocker.

doi:10.1371/journal.pone.0124844.t001
Fig 2. Cardiac peptides and left ventricular ejection fraction (LVEF) in control and HF patients.

Ambulatory patients with clinical diagnosis of HFrEF (n = 24), HFrEF (n = 20), and age-matched controls (n = 38) were selected for metabolomics analysis as part of the Alberta HEART (Heart Failure Etiology and Analysis Research Team) project. Plasma BNP and NT-proBNP levels were measured using a Biosite Triage reagent pack and Elecsys 2010 proBNP assay, respectively. LVEF was assessed by echocardiography and interpreted by cardiologists blinded to the metabolomics analysis. Data are presented as the median ± IQR. * p < 0.05 compared to the control group, # p < 0.05 compared to the HFpEF group.

doi:10.1371/journal.pone.0124844.g002
significant an NRI of 0.439 ($p = 0.0807$) and an IDI of 0.098 ($p = 0.0547$)). On the other hand, the blended (metabolites+NT-proBNP) model was significantly better than the NT-proBNP-only model (a NRI of 0.952 ($p < 0.0001$) and IDI of 0.222 ($p < 0.0001$)).

Metabolomic differences between HFrEF and controls

The metabolomic analysis showed that the serum concentrations of some short and medium-chain acylcarnitines, carnitine, creatinine, creatine, betaine, and some amino acids were higher in HFrEF patients than non-HF controls. Whereas, the serum concentrations of several PCs, LysoPC(C18:2), LysoPC(C20:4), some sphingomyelins, acetate, acetoacetate, 2-hydroxybutyrate, and 3-hydroxybutyrate were found to be lower in HFrEF patients than non-HF controls (Fig 5, S2 Table).

For the identification of a potential biomarker panel of metabolites, we performed a similar LR analysis of metabolites from HFrEF patients and non-HF controls. Another small number of metabolites including creatinine, carnitine, acetocetate, LysoPC(C18:2), LysoPC(C20:4), and 2-hydroxybutyrate discriminated HFrEF patients from control subjects. ROC curve analysis produced an AUC of 0.959 (Fig 6A and Table 2). An additional LR model was developed incorporating acetocetate (Fig 6B) and NT-proBNP. ROC curve analysis of this model shows that it produced a striking AUC of 0.997 (Fig 6A). The p-value of permutation test was less than 0.0005. When all models were compared, the models that included NT-proBNP had higher AUC values than the model that used metabolites only. Nevertheless, similar to the
Fig 4. (A) Receiver operator characteristic (ROC) analysis for serum metabolites, cardiac peptides, and combined metabolites and NT-proBNP. Logistic regression (LR) was performed to find the most parsimonious model to discriminate HFpEF patients from control subjects using the minimum number of metabolites and/or cardiac peptides. Octanoylcarnitine, arginine, asparagine, lysophosphatidylincholine acyl C18:2, and sphingomyelin C20:2 were used in the metabolites-only panel. While octanoylcarnitine, arginine, and sphingomyelin C20:2 were used for the combined metabolites and NT-proBNP panel. (B–D) Quantification of the metabolites used to derive the LR equation of the combined metabolites and NT-proBNP model. Data are presented as means ± SD. * p < 0.05 compared to the control group.

doi:10.1371/journal.pone.0124844.g004
Table 2. Unadjusted Comparisons.

| Model | AUC   | Sensitivity | Specificity | NRI (95% CI)      | p-value | IDI (95% CI)      | p-value |
|-------|-------|-------------|-------------|--------------------|---------|--------------------|---------|
|       |       | HFPoEF vs. Control |       | | | |
| BNP   | 0.816 | 0.750       | 0.763       | 1.276 (0.898–1.655) | < 0.0001| 0.341 (0.237–0.445)| < 0.0001|
| NT-proBNP | 0.853 | 0.792       | 0.789       | 0.952 (0.513–1.391) | < 0.0001| 0.222 (0.122–0.321)| < 0.0001|
| Metabolites only | 0.924 | 0.833       | 0.895       | 0.439 (0.054–0.931) | 0.0807  | 0.0807 (0.002–0.199)| 0.0547 |
| NT-proBNP & Metabolites | 0.942 | 0.917       | 0.921       | -                  | -       | -                  | -       |
|       |       | HFRoEF vs. Control |       | | | |
| BNP   | 0.942 | 0.850       | 0.842       | 0.355 (0.142–0.569) | 0.0011  | 0.313 (0.193–0.433)| < 0.0001|
| NT-proBNP | 0.991 | 0.950       | 0.947       | 0.153 (-0.051–0.356)| 0.1421  | 0.103 (-0.001–0.208)| 0.0527 |
| Metabolites only | 0.959 | 0.900       | 0.895       | 0.434 (0.208–0.661) | 0.0002  | 0.248 (0.104–0.392)| 0.0007 |
| NT-proBNP & Metabolites | 0.997 | 0.950       | 0.974       | -                  | -       | -                  | -       |

The NRI and IDI values are of the blended "natriuretic peptide & metabolites" model versus each individual model.

AUC = Area Under the Curve, NRI = Net Reclassification Improvement, IDI = Integrated Discrimination Improvement, CI = Confidence Interval

doi:10.1371/journal.pone.0124844.t002

Fig 5. Heat map of metabolomic differences between HFRoEF and controls. Heat maps were generated with the concentrations of potential candidate metabolites with univariate analysis. Similar metabolites were arranged together for use in pathway analysis through intuitive pattern discovery. The heat map displays an increase in each metabolite in relative concentration as a red color and a decrease in a metabolite as a blue color. The metabolites are listed at the left side of each row, and the subjects are shown at the bottom of each column.

doi:10.1371/journal.pone.0124844.g005
Fig 6. (A) Receiver operator characteristic (ROC) analysis for serum metabolites, cardiac peptides, and combined serum metabolites and NT-proBNP. Logistic regression (LR) was performed to find the most parsimonious model to discriminate HFrEF patients from control subjects using the minimum number of metabolites and/or cardiac peptides. Creatinine, carnitine, acetoacetate, lysophosphatidylcholine acyl C18:2, 2-hydroxybutyrate, and lysophosphatidylcholine acyl C20:4 were used in the metabolites-only panel. While acetoacetate was used for the combined metabolites and NT-proBNP panel. (B) Quantification of acetoacetate which was used to derive the LR equation of the combined metabolites and NT-proBNP model. Data are presented as means ± SD. * p < 0.1 compared to the control group.

doi:10.1371/journal.pone.0124844.g006
HFpEF models, the model that combined both the NT-proBNP+metabolites achieved the highest AUC value (Fig 6A, Table 2, and S4 Table) with an NRI of 0.434 (p = 0.0002) and an IDI of 0.248 (p = 0.0007) compared to metabolites alone. However, NT-proBNP+metabolites was not significantly better than the NT-proBNP model with a NRI of 0.153 (p = 0.1421) and IDI of 0.103 (p = 0.0527).

**Metabolomic differences between HFpEF and HFrEF**

For the metabolomic data, long-chain acylcarnitines, 2-hydroxybutyrate, 3-hydroxybutyrate, and acetate were found to be higher in the HFpEF group than the HFrEF group, while SM(C24:1), some PCs and LysoPCs were found to be lower in the HFpEF group than the HFrEF group (Fig 7 and S3 Table). In order to identify a panel of selected metabolites that can discriminate between HFpEF and HFrEF, we performed a similar LR analysis. A panel of 4 metabolites (2-hydroxybutyrate, octadecenoylcarnitine (C18:1), hydroxyprionylcarnitine (C3-OH), and SM(C24:1)) was identified that discriminated between HFpEF and HFrEF. Using only these metabolites, ROC curve analysis produced an AUC of 0.908 (Fig 8A and Table 2). Permutation testing (p-value < 0.0185) for model validation indicated that the model was statistically significant.

LR including the metabolites and natriuretic peptides was also performed. This model utilized acetate (Fig 8B), 2-hydroxybutyrate (Fig 8C), pimelylcarnitine (Fig 8D), and PC(C40:4) (Fig 8D)
as the metabolites and BNP. ROC curve analysis of this model produced an AUC of 0.981 (Fig 8A) with a permutation test p-value of <0.0005. As before, the model that combined BNP with the metabolites achieved the highest AUC value (Fig 8A, Table 2, and S4 Table). This blended model had a NRI of 0.275 (p = 0.0484) and an IDI of 0.248 (p = 0.0031) compared to metabolites alone and a NRI of 0.95 (p<0.00001) and an IDI of 0.569 (p<0.00001) compared to BNP alone.

Discussion

Several potential metabolic perturbations have been discovered in HF patients in the current study. Although some of these metabolite profile differences were observed in both HFPpEF and HFrEF, there are several pathways that are differentially altered in HFPpEF versus HFrEF. For instance, we discovered that serum concentrations of short-chain acylcarnitines are higher in both HFPpEF and HFrEF patients than non-HF controls, while medium and long-chain acylcarnitines were higher in HFPpEF patients than both HFrEF patients and non-HF controls. Carnitine and its acyl derivatives play a key role in fatty acid uptake and mitochondrial metabolism [23], hence an increase in acylcarnitines may imply inefficient β-oxidation [24] in HFPpEF patients. In addition, several reports have demonstrated the detrimental effects of long-chain acylcarnitines, as they are pro-inflammatory [25] and arrhythmogenic [26]. A recent report has shown that plasma levels of long-chain acylcarnitines predict cardiovascular mortality in dialysis patients [27]. Therefore, high serum concentration of long-chain acylcarnitines in HFPpEF patients may corroborate the findings that show inflammation is strongly associated with diastolic dysfunction [27]. It may also explain the recent findings that the expression of the pro-inflammatory tumor necrosis factor-alpha receptor 2 (TNFR2) is higher in HFPpEF than in HFrEF patients [28]. Moreover, due to their arrhythmogenic properties, higher concentrations of long-chain acylcarnitines may explain the high prevalence of atrial fibrillation among HFPpEF patients, as observed in our cohort and in other studies [29].

In addition to increases in acyl derivatives in HFPpEF compared to HFrEF, the serum carnitine levels were also higher in both HFPpEF and HFrEF patients compared to controls. Since the myocardial content of carnitine tends to be lower in HF patients [30], higher serum carnitine level can be attributed to a leakage of carnitine from the myocardium to the blood. Our findings are in agreement with other studies showing that plasma carnitine levels are higher in HF patients than controls [31].

Several other metabolic perturbations were observed in our patient cohorts that warrant discussion. For instance, the serum concentrations of creatinine and several amino acids are higher in both HFPpEF and HFrEF patients than non-HF controls. The higher creatinine concentration in HF patients may be secondary to the renal impairment commonly observed in HF patients [32], while the increase in the amino acids may imply a hypercatabolic state that has been reported in chronic HF patients [12, 33]. Conversely, serum concentrations of PCs, LysoPCs, and SM were lower in HFPpEF and HFrEF patients compared to controls. The decrease in these phospholipids along with an increase in the serum concentration of betaine may indicate a shift in choline metabolism toward more betaine and less PC production. This is of potential interest as choline deficiency has been reported to cause cardiac dysfunction [34] and may be involved in the pathogenesis of HF. These findings are consistent with animal models, where PCs and other phospholipids were found to be lower in heart tissues from Syrian hamsters with hereditary cardiomyopathy compared to normal hamsters [35]. Together, these findings highlight the potential role of choline metabolism in the pathogenesis of both HFPpEF and HFrEF.

Other metabolic abnormalities were observed in HFrEF patients only. For instance, creatine levels were found to be higher in HFrEF patients than controls. Phosphocreatine is converted
Logistic regression (LR) was performed to find the most parsimonious model to discriminate HFpEF from HFrEF patients using the minimum number of metabolites and/or cardiac peptides. 2-hydroxybutyrate, octadecenoylcarnitine (C18:1), hydroxyprionylcarnitine (C3-OH), and sphingomyelin C24:1 were used in the metabolites-only panel. While acetate, 2-hydroxybutyrate, pinemyl carnitine, and phosphatidyl choline diacyl C40:4 were used for the combined metabolites and NT-proBNP panel.

(B–E) Quantification of the metabolites used to derive the LR equation of the combined metabolites and NT-proBNP model. Data are presented as means ± SD. The dashed line represents the metabolite concentration in control subjects. * p < 0.05 compared to the HFpEF group.

doi:10.1371/journal.pone.0124844.g008
to creatine to produce ATP which is an essential energy source for myocardial contraction [36]; therefore, increased serum creatine levels may indicate a state of energy depletion. Notably, two previous metabolomics studies have demonstrated higher serum creatine levels in HF patients [12, 37].

In contrast to creatine, the serum concentrations of the ketone bodies, acetoacetate, 2-hydroxybutyrate and 3-hydroxybutyrate were lower in HFrEF patients than both HfP EF patients and non-HF controls. This may imply a greater reliance on ketone bodies as an energy source in HFrEF patients. In contrast to our results, older studies have shown that blood ketone bodies are higher in HF patients than in healthy control subjects after 8–12 hr fasting [38, 39]. More recently, it has been shown that there was no significant difference in plasma 2-hydroxybutyrate levels between HF patients without diabetes and controls [40]. Fasting, the severity of HF, and other co-morbidities may be the reason for the varying results. However, metabolic studies cannot determine whether a metabolite is reduced because of decreased production, increased degradation and/or uptake, or both [41]. Neither can we be certain on what organ(s) are responsible for the changes observed in the serum of these patients. Further research is warranted to elucidate the mechanisms of the metabolic perturbations reported in this study.

Since we have identified distinct metabolomic fingerprints of HfP EF and HFrEF, we sought to use these fingerprints to discover novel panels of biomarkers that can be used to help differentiate between HfP EF and HFrEF. Although the cardiac peptides, BNP and NT-proBNP, are considered gold standards for the diagnosis of HF [42, 43], the sensitivity and specificity of these cardiac peptides can be significantly affected by several confounding factors including age, obesity, sex, as well as pulmonary, hepatic, and renal dysfunction [14]. Consequently, the utility of cardiac peptides as biomarkers to identify HfP EF patients is questionable. While some studies have shown that these peptides can distinguish HfP EF patients from controls [14, 44–47], other studies have demonstrated that these peptides are not reliable enough for the diagnosis of HfP EF [48–50]. However, using only three metabolites (octanoyl carnitine, arginine, and SM(C20:2)) along with NT-proBNP, we discovered a novel panel of biomarkers that reliably distinguishes HfP EF from control subjects. Using this panel, we obtained a ROC AUC of 0.942. Of interest, a panel of 3 myocardial matrix biomarkers (MMP-2, TIMP-4, and MMP-8) has been combined with clinical variables to produce a ROC AUC of 0.79 for diagnosing HfP EF [14]. Similarly, combining BNP and MMP-2 has been shown to diagnose HfP EF with 0.81 sensitivity and 0.83 specificity [44]. In addition, soluble ST2 (suppression of tumorigenicity 2, a blood protein confirmed to act as a decoy receptor for interleukin-33) has been shown to be a potential biomarker for HfP EF with an AUC of 0.80 for its ROC curve [45]. In comparison, our newly identified panel of metabolites far exceeds the accuracy of existing panels of protein biomarkers and may have potential to be used clinically in the diagnosis of HfP EF.

In contrast to the diagnosis of HfP EF, the standard cardiac peptides produced very high ROC AUCs in our study, suggesting that these cardiac peptides are reliable biomarkers to distinguish HFrEF patients from controls. Nevertheless, LR analysis of the metabolites combined with the standard cardiac peptides revealed that measuring only one metabolite (acetoacetate) along with the NT-proBNP increased the AUC of the ROC curve from 0.991 for NT-proBNP alone to 0.997 for the acetoacetate plus the NT-proBNP. Taking into account the confounding factors that may limit the diagnostic utility of these cardiac peptides [14], the addition of measuring acetoacetate along with plasma natriuretic peptides may be of clinical importance; although they still cannot be used to accurately differentiate between HFrEF and HfP EF patients [51]. In fact, BNP and NT-proBNP produced ROC curves with relatively low AUC values of 0.727 and 0.696 for BNP and NT-proBNP, respectively, when used to distinguish between HfP EF and HFrEF patients in our cohort. However, we identified a novel panel of 4 metabolites that when used along with BNP, produced a ROC AUC value of 0.981 to distinguish
HFrEF patients from HFpEF patients. To the best of our knowledge, this is the first report to identify a set of biomarkers that can differentiate between HFpEF and HFrEF patients with such a high level of accuracy.

Several limitations to our current study warrant further discussion. First, a relatively small number of patients were enrolled in each HF group. Therefore, the metabolites identified in this study need to be verified by larger, prospective, validation cohort. Nevertheless, the high ROC AUC values for this small patient number suggest the high potential of these metabolites to play an important role in HF diagnosis. In addition, the metabolomic profile is a collective snapshot of all the metabolic perturbations that may include confounding factors such as other disease states, acute illnesses, or medication use [12]. Therefore, we cannot be certain that the observed metabolic perturbations are solely attributable to the HFpEF or the HFrEF syndrome. Of interest, there was no significant difference in all the demographic and clinical data between the HFpEF and the HFrEF groups except that CAD was more prevalent in HFrEF group than in the HFpEF group. Although this may represent a confounding factor, it is consistent with the overall epidemiology of HFpEF and HFrEF [52]. However, the metabolites that differentiate between HFpEF and HFrEF groups in the current study were adjusted to account for the difference in the prevalence of CAD between the two groups. As such, the metabolic differences between HFpEF and HFrEF patients cannot be attributed to any demographic, medication, or other disease state factors.

In conclusion, this study is the first to investigate the metabolomic profile of HFpEF and HFrEF patients compared to non-HF controls. The unbiased and systematic approach employed in this metabolomic study enabled us to identify a metabolic fingerprint of both HFpEF and HFrEF in addition to three panels of metabolites that can be used to diagnose these conditions. We chose a LR model to ensure that our results would have clear clinical utility. This is because LR produces a simple equation with a defined threshold that can be used to classify individuals. Therefore, once our findings are externally validated and refined, our work may allow a simple decision tree that would aid in the rapid diagnosis of HFpEF. In summary, we have used quantitative metabolomics to identify a novel panel of blood-based metabolites that when used in combination with natriuretic peptides, can accurately identify HFpEF patients and distinguish between HFpEF and HFrEF patients.

Supporting Information

S1 Table. Univariate Analysis of HFpEF vs. Control.
(DOCX)

S2 Table. Univariate Analysis of HFrEF vs. Control.
(DOCX)

S3 Table. Univariate analysis of HFrEF vs. HFpEF.
(DOCX)

S4 Table. Logistic regression Analyses for the Models.
(DOCX)

Acknowledgments

We gratefully acknowledge the patients who have volunteered their time for this study. We also acknowledge the assistance of Program Manager, Kelly Narine and research coordinators; Marleen Irwin, Lisa Fay, Darlene Ramadan and Leslie Jackson-Carter.
Author Contributions
Conceived and designed the experiments: BNZ MMS JE GO DW JRBD. Performed the experiments: RM TCB SB. Analyzed the data: BNZ BH. Contributed reagents/materials/analysis tools: DW JRBD. Wrote the paper: BNZ MMS JE BH TA GO DW JRBD.

References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2014 update: a report from the American heart association. Circulation. 2014; 129(3):e28–e292. doi: 10.1161/01.CIR.0000441139.02102.80 PMID: 24352519
2. Dunlay SM, Roger VL. Understanding the Epidemic of Heart Failure: Past, Present, and Future. Curr Heart Fail Rep. 2014.
3. Abhayaratna WP, Marwick TH, Smith WT, Becker NG. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart. 2006; 92(9):1259–64. PMID: 16488928
4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006; 355(3):251–9. PMID: 16855265
5. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28(20):2539–50. PMID: 17428622
6. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012; 33(14):1750–7. doi: 10.1093/eurheartj/ehs254 PMID: 21821849
7. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14(8):803–69. doi: 10.1093/eurjhf/hfs105 PMID: 22626712
8. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011; 32(6):670–9. doi: 10.1093/eurheartj/ehq226 PMID: 21138935
9. Du ZY, Shen A, Su L, Liang JQ, Xu DL. [Application of (1)H-NMR-based pattern recognition in serum metabolomics of patients with chronic heart failure]. Nan Fang Yi Ke Da Xue Xue Bao. 2012; 32(3):415–9. PMID: 22445997
10. Dunn WB, Broadhurst DI, Deepak SM, Buch MH, McDowell G, Spasic I, et al. Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics. 2007; 3(4):413–26.
11. Kang SM, Park JC, Shin MJ, Lee H, Oh J, Ryu do H, et al. (1)H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin Biochem. 2011; 44(4):293–9. doi: 10.1016/j.clinbiochem.2010.11.010 PMID: 21167146
12. Wang J, Li Z, Chen J, Zhao H, Luo L, Chen C, et al. Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure. Mol Biosyst. 2013; 9(11):2618–26. doi: 10.1039/c3mb70227h PMID: 23959290
13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16):e147–e239. doi: 10.1016/j.jacc.2013.05.019 PMID: 23747642
14. Zile MR, Baicu CF. Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res. 2013; 6(4):501–15. doi: 10.1007/s12265-013-9472-1 PMID: 23716130
15. van Veldhuisen DJ, Linssen GC, Jaaarsma T, van Gilst WH, Hoes AW, Tijssen JG, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013; 61(14):1488–506. doi: 10.1016/j.jacc.2012.12.044 PMID: 23500300
16. Mamas M, Dunn WB, Neyses L, Goodacre R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol. 2011; 85(1):5–17. doi: 10.1007/s00204-010-0609-6 PMID: 20953584
17. Ezekowitz JA, Becher H, Belenkie I, Clark AM, Duff LJ, Friedrich MG, et al. The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovasc Disord. 2014; 14(1):91.
18. Bionda C, Bergerot C, Ardail D, Rodriguez-Lafrasse C, Rousson R. Plasma BNP and NT-proBNP assays by automated immunoanalyzers: analytical and clinical study. Ann Clin Lab Sci. 2006; 36(3):299–306. PMID: 16951271

19. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, et al. The human serum metabolome. PLoS One. 2011; 6(2):e16957. doi: 10.1371/journal.pone.0016957 PMID: 21359215

20. Ojala M, Garriga GC. Permutation Tests for Studying Classifier Performance. J Mach Learn Res. 2010; 11:1833–63.

21. Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, Macdonald IA, et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem. 2006; 78 (2):567–74. PMID: 16408941

22. Pencina MJ, D'Agostino RB Sr., D'Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27 (2):157–72; discussion 207–12. PMID: 17569110

23. Marcovina SM, Sirtori C, Peracino A, Gheorghiade M, Borum P, Remuzzi G, et al. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Transl Res. 2013; 161 (2):73–84. doi: 10.1016/j.trsl.2012.10.006 PMID: 23138103

24. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr. 2009; 139(6):1073–81. doi: 10.3945/jn.108.103754 PMID: 19369366

25. Rutkowsky JM, Knotts TA, Ono-Moore KD, McCoin CS, Huang S, Schneider D, et al. Acylcarnitines activate proinflammatory signaling pathways. Am J Physiol Endocrinol Metab. 2014; 306(2):E1378–87. doi: 10.1152/ajpendo.00656.2013 PMID: 24760988

26. Ferro F, Ouille A, Tran TA, Fontanaud P, Bois P, Babuty D, et al. Long-chain acylcarnitines regulate the hERG channel. PLoS One. 2012; 7(7):e41686. doi: 10.1371/journal.pone.0041686 PMID: 22848566

27. Kalim S, Clish CB, Wenger J, Elmariah S, Yeh RW, Deferio JJ, et al. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc. 2013; 2(6):e000542. doi: 10.1161/JAHA.113.000542 PMID: 24308938

28. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, et al. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One. 2014; 9(6):e99495. doi: 10.1371/journal.pone.0099495 PMID: 24923671

29. Zakari R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation. 2013; 128(10):1085–93. doi: 10.1161/CIRCULATIONAHA.113.01475 PMID: 23908348

30. Martin MA, Gomez MA, Guillem F, Bornstein B, Campos Y, Rubio JC, et al. Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim Biophys Acta. 2000; 1502(3):330–6. PMID: 11068176

31. El-Aroussy W, Mayhoub G, Alem SA, El-Tobgy S, Mokhtar MS. Plasma carnitine levels as a marker of impaired left ventricular functions. Mol Cell Biochem. 2000; 213(1–2):37–41. PMID: 11129963

32. Zamora E, Lupon J, de Antonio M, Vila J, Penafiel J, Galan A, et al. Long-Term Prognostic Value for Patients with Chronic Heart Failure of Estimated Glomerular Filtration Rate Calculated with the New CKD-EPI Equations Containing Cystatin C. Clin Chem. 2013.

33. Pasini E, Aquilani R, Diquard FS, D’Antona G, Gheorghiade M, Taegtmeyer H. Hypercatabolic syndrome: molecular basis and effects of nutritional supplements with amino acids. Am J Cardiol. 2008; 101(11A):11E–5E. doi: 10.1016/j.amjcard.2008.02.074 PMID: 18514619

34. Strialkou AA, Lazaris AC, Perelas AI, Mourouzis IS, Douizis I, Karkalousos PL, et al. Heart dysfunction induced by choline-deficiency in adult rats: the protective role of L-carnitine. Eur J Pharmacol. 2013; 709(1–3):20–7. doi: 10.1016/j.ejphar.2013.03.040 PMID: 23567070

35. Okumura K, Yamada Y, Kondo J, Hashimoto H, Ito T, Kitoh J. Decreased 1,2-diacylglycerol levels in skeletal muscle in elderly people: their association with sarcopenia. J Nutr Health Aging. 2014; 18(1):81–6. doi: 10.1007/s12603-013-0257-2

36. Haris M, Singh A, Cai K, Kogan F, McGarvey J, Debroese C, et al. A technique for in vivo mapping of myocardial creatine kinase metabolism. Nat Med. 2014.

37. Tenori L, Hu X, Pantaleo P, Alterini B, Castelli G, Olivotto I, et al. Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance spectroscopy analysis. Int J Cardiol. 2013; 168(4):e113–5. doi: 10.1016/j.ijcard.2013.08.042 PMID: 24007967
38. Lommi J, Kupari M, Koskinen P, Naveri H, Leinonen H, Pulikki K, et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol. 1996; 28(3):665–72. PMID: 8772754

39. Lommi J, Koskinen P, Naveri H, Harkonen M, Kupari M. Heart failure ketosis. J Intern Med. 1997; 242(3):231–B. PMID: 9350168

40. Melanovský V, Kotrc M, Polak J, Pelikanova T, Bendlova B, Cahova M, et al. Availability of energetic substrates and exercise performance in heart failure with or without diabetes. Eur J Heart Fail. 2012; 14(7):754–63. doi: 10.1093/eurjhf/hfs080 PMID: 22696515

41. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem. 2012; 58(1):139–47. doi: 10.1373/clinchem.2011.169573 PMID: 22110018

42. Thomas MD, Fox KF, Wood DA, Gibbs JS, Coats AJ, Henein MY, et al. Echocardiographic features and brain natriuretic peptides in patients presenting with heart failure and preserved systolic function. Heart. 2006; 92(5):603–8. PMID: 16159966

43. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol. 2004; 43(1):55–60. PMID: 14715184

44. Martos R, Baugh J, Ledwidge M, O’Loughlin C, Murphy NF, Conlon C, et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009; 11(2):191–7. doi: 10.1093/eurjhf/hfn036 PMID: 19168518

45. Wang YC, Yu CC, Chiu FC, Tsai CT, Lai LP, Hwang JJ, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail. 2013; 19(3):163–8. doi: 10.1016/j.cardfail.2013.01.010 PMID: 23482076

46. Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005; 26(21):2277–84. PMID: 16014646

47. Jorge AJ, Freire MD, Ribeiro ML, Fernandes LC, Lanzieri PG, Jorge BA, et al. [Utility of B-type natriuretic peptide measurement in outpatients with heart failure with preserved ejection fraction]. Rev Port Cardiol. 2013; 32(9):647–52. doi: 10.1016/j.repdc.2012.10.019 PMID: 23910641

48. Anjan VY, Loftus TM, Burke MA, Akhtar N, Fonarow GC, Gheorghiade M, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012; 110(6):870–6. doi: 10.1016/j.amjcard.2012.05.014 PMID: 22681864

49. Lukacs I, Fey E, Karpati P. [Experiences with serum BNP (B type natriuretic peptide) in patients with systolic and diastolic heart failure]. Orv Hetil. 2005; 146(37):1919–23. PMID: 16255376

50. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol. 2003; 92(12):1434–8. PMID: 14675580

51. Fonseca C, Sarmento PM, Minea A, Goncalves E, Covas R, Dias AR, et al. Comparative value of BNP and NT-proBNP in diagnosis of heart failure. Rev Port Cardiol. 2004; 23(7–8):979–91.

52. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013; 10(4):401–10. PMID: 24078336